Retatrutide

Retatrutide (LY-3437943)

Retatrutide is a research grade peptide studied in various clinical trials as a triple-agonist, acting on the GIP, GLP-1, and glucagon receptors.

This unique combination is central in scientific research on energy balance, fat metabolism, and appetite regulation.

Research Findings:
In phase-2 studies by Eli Lilly, published in the New England Journal of Medicine (2023), participants experienced an average weight reduction of 17–24% over 24–48 weeks (depending on dose and duration).
Researchers also observed improvements in metabolic markers, including reductions in HbA1c in people with type 2 diabetes.
Further studies are currently examining the long-term safety and mechanisms of action of Retatrutide as a model for combined incretin agonists.

Research Context:
Retatrutide is used in laboratories and research institutions to analyze the effects of triple-agonism on metabolism, fat oxidation, and energy expenditure.
It is strictly intended for in-vitro research, reference standards, and preclinical research purposes.
Not developed or approved for medical, cosmetic, or therapeutic use.

Important Information:

• For laboratory research only
• Not intended for human consumption or injection
• Exclusively for research and development purposes
• Buyers are responsible for compliance with local laws and regulations
• Seller is not liable for improper or unauthorized use